IMA901 (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 for US, EU5 and Japan
The report also includes information on Renal Cell Carcinoma market.01/17/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 17, 2013 Category: Cancer & Oncology Source Type: news

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC.01/15/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2013 Category: Cancer & Oncology Source Type: news

Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review
This report provides elemental information and data relating to the clinical trials on Kidney Cancer (Renal Cell Cancer).01/09/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 9, 2013 Category: Cancer & Oncology Source Type: news

Renal cell carcinoma and the WNT/ β-catenin pathway
The highly conserved WNT pathway is involved in the transduction of signals from the cell surface to the nucleus, and it is known to play a key role in embryonic development, adult tissue maintenance and tumourigenesis (Klaus & Birchmeier, 2008). 11/11/2012 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 11, 2012 Category: Urology & Nephrology Source Type: news

Advances in advanced renal cell carcinoma from ESMO
Professor Tim Eisen from Addenbrooke's Oncology Centre, Cambridge, talks to ecancer TV with Dr Bernard Escudier from Institut Gustave Roussy, France, Dr Thomas Powles from St Bartholomew Hospital, London, and Dr Thomas Hutson from Baylor Sammons Cancer Center, USA. The experts outline results from the major studies reporting at ESMO 2012 in mRCC. 10/18/2012 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 18, 2012 Category: Urology & Nephrology Source Type: news

Advances in advanced renal cell carcinoma from ESMO
Professor Tim Eisen from Addenbrooke's Oncology Centre, Cambridge, talks to ecancer TV with Dr Bernard Escudier from Institut Gustave Roussy, France, Dr Thomas Powles from St Bartholomew Hospital, London, and Dr Thomas Hutson from Baylor Sammons Cancer Center, USA. The experts outline results from the major studies reporting at ESMO 2012 in mRCC.10/18/2012 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 18, 2012 Category: Urology & Nephrology Source Type: news

WILEX AG announces results of Phase III ARISER study with RENCAREX ® in clear cell renal cell carcinoma
Trial did not meet its primary endpoint of median disease-free survival (DFS) 10/17/2012 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 17, 2012 Category: Urology & Nephrology Source Type: news

Researchers Receive Grants from NCCN Oncology Research Program Funded through AVEO/Astellas Collaboration
The NCCN Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib as a result of funding through the AVEO/Astellas collaboration. FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These gr... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - October 15, 2012 Category: Cancer & Oncology Source Type: news

Chromophobe Renal Cell Carcinoma with Osteosarcoma Differentiation
We present a 6th case of sarcomatoid chromophobe renal cell carcinoma, which had an osteosarcoma differentiation component. However, the correlation between the presence of heterologous elements and prognosis is unknown because of the rarity of this phenomenon.04/24/2012 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 26, 2012 Category: Cancer & Oncology Source Type: news

Navigating Treatment Decisions
This article focuses on treatment for clear cell disease, but some of these treatments are also appropriate for patients with non-clear cell disease. Some patients may have only a single metastatic tumor that can be removed by surgery. But most patients with metastatic disease have tumors in many parts of the body. In order to treat all of these tumors, patients are given systemic therapies, which are drugs that travel through the bloodstream and can directly reach cells throughout the body. Immunotherapy is a type of treatment that gives a boost to the immune system. The goal of immunotherapy is to help the patient&rs...
Source: Kidney Cancer Association - February 7, 2012 Category: Urology & Nephrology Source Type: news

Navigating Treatment Decisions
This article focuses on treatment for clear cell disease, but some of these treatments are also appropriate for patients with non-clear cell disease. Some patients may have only a single metastatic tumor that can be removed by surgery. But most patients with metastatic disease have tumors in many parts of the body. In order to treat all of these tumors, patients are given systemic therapies, which are drugs that travel through the bloodstream and can directly reach cells throughout the body. Immunotherapy is a type of treatment that gives a boost to the immune system. The goal of immunotherapy is to help the patient&rsqu...
Source: Kidney Cancer Association - February 7, 2012 Category: Urology & Nephrology Source Type: news

Summary: International Kidney Cancer Symposium
Conclusions VHL/PBRM1 mutations confirmed 3rd subtype identified and under review but appears to be mis-classified tumors.  Shows value of molecular methods rather than new mechanistic insights. Integration with survival outcome—suggests molecular detailing can be prognostic Full integrative analysis in process Preliminary data can be found at http://tcga-data.nci.hih.gov/tcga/ FoxO Transcription Factors in mTORC1- Activated Renal Tumorigenesis:  Implications for the RCC Treatment Boyi Gan, MD Anderson Cancer Center FoxO Family Transcription Factors:  mammals possess FoxO...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

Summary: International Kidney Cancer Symposium
Conclusions VHL/PBRM1 mutations confirmed 3rd subtype identified and under review but appears to be mis-classified tumors.  Shows value of molecular methods rather than new mechanistic insights. Integration with survival outcome—suggests molecular detailing can be prognostic Full integrative analysis in process Preliminary data can be found athttp://tcga-data.nci.hih.gov/tcga/ FoxO Transcription Factors in mTORC1- Activated Renal Tumorigenesis:  Implications for the RCC Treatment Boyi Gan, MD Anderson Cancer Center FoxO Family Transcription Factors:  mammals possess FoxO1, FoxO3, FoxO4 an...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

Summaries: International Kidney Cancer Symposium
Conclusion: there is no increased risk of doing the lymph node dissection early on.   Dr. Eggener-CON   Basics Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients.  A Mayo study revealed no data showing therapeutic benefit in high risk patients.  For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit. Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nod...
Source: Kidney Cancer Association - November 29, 2011 Category: Urology & Nephrology Source Type: news

Summaries: International Kidney Cancer Symposium
Conclusion: there is no increased risk of doing the lymph node dissection early on. Dr. Eggener-CON  Basics Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients.  A Mayo study revealed no data showing therapeutic benefit in high risk patients.  For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit. Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nodes.  A tumor> 10 cm w...
Source: Kidney Cancer Association - November 29, 2011 Category: Urology & Nephrology Source Type: news

Brigham and Women ’s Researchers Present Findings at the 10th Annual AACR International Conference on Frontiers in Cancer Prevention Research
Researchers find links between coffee consumption and skin cancer risk, tanning bed use and skin cancer risk, and analgesic use and renal cell carcinoma. (Source: BWH News)
Source: BWH News - October 24, 2011 Category: Hospital Management Source Type: news

Brigham and Women ’s Researchers Present Findings at the 10th Annual AACR International Conference on Frontiers in Cancer Prevention Research
Researchers find links between coffee consumption and skin cancer risk, tanning bed use and skin cancer risk, and analgesic use and renal cell carcinoma. (Source: BWH for Journalists)
Source: BWH for Journalists - October 24, 2011 Category: Research Source Type: news

Brigham and Women ’s Researchers Present Findings at the 10th Annual AACR International Conference on Frontiers in Cancer Prevention Research
Researchers find links between coffee consumption and skin cancer risk, tanning bed use and skin cancer risk, and analgesic use and renal cell carcinoma. (Source: BWH News)
Source: BWH News - October 24, 2011 Category: Hospital Management Source Type: news

VeriStrat ® Results Correlate with Survival Outcomes in Kidney Cancer Patients
Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent ®) and erlotinib (Tarceva®), by survival outcomes. 10/17/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 17, 2011 Category: Urology & Nephrology Source Type: news

When it comes to fighting cancer, one size doesn’t fit all
 Download this article as a PDF WHEN IT COMES TO FIGHTING CANCER, ONE SIZE DOESN’T FIT ALL Why disease-specific organizations are vital to research, patient support and advocacy One of the most significant results of the online revolution of the last two decades has been the creation of information communities, organized around highly specialized topics. The monolithic, top down, one-size-fits-all mentality that characterized organizational structures and information exchange in the mid-20th century is gone. We’re more focused and more targeted today -- connected with people who share our interests, our pa...
Source: Kidney Cancer Association - July 8, 2011 Category: Urology & Nephrology Source Type: news

When it comes to fighting cancer, one size doesn ’t fit all
  Download this article as a PDF WHEN IT COMES TO FIGHTING CANCER, ONE SIZE DOESN & rsquo;T FIT ALL Why disease-specific organizations are vital to research, patient support and advocacy One of the most significant results of the online revolution of the last two decades has been the creation of information communities, organized around highly specialized topics. The monolithic, top down, one-size-fits-all mentality that characterized organizational structures and information exchange in the mid-20th century is gone. We & rsquo;re more focused and more targeted today -- connected with people who share...
Source: Kidney Cancer Association - July 8, 2011 Category: Urology & Nephrology Source Type: news

When it comes to fighting cancer, one size doesn ’t fit all
 Download this article as a PDFWHEN IT COMES TO FIGHTING CANCER, ONE SIZE DOESN’T FIT ALLWhy disease-specific organizations are vital to research, patient support and advocacyOne of the most significant results of the online revolution of the last two decades has been the creation of information communities, organized around highly specialized topics.The monolithic, top down, one-size-fits-all mentality that characterized organizational structures and information exchange in the mid-20th century is gone.We’re more focused and more targeted today -- connected with people who share our interests, our passion...
Source: Kidney Cancer Association - July 8, 2011 Category: Urology & Nephrology Source Type: news

Vaccine for Advanced Kidney Cancer
The pivotal Phase III study will evaluate as the primary endpoint the overall survival of advanced renal cell carcinoma patients treated with IMA901 in combination with Pfizer's Sutent(R) (sunitinib malate) versus Sutent(R) alone.   Read the full article online .04/12/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 13, 2011 Category: Urology & Nephrology Source Type: news

Vaccine for Advanced Kidney Cancer
The pivotal Phase III study will evaluate as the primary endpoint the overall survival of advanced renal cell carcinoma patients treated with IMA901 in combination with Pfizer's Sutent(R) (sunitinib malate) versus Sutent(R) alone. Read the full article online.04/12/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 13, 2011 Category: Urology & Nephrology Source Type: news

Clinical Trial: Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
In this podcast Brian Rini, M.D., a member of the Kidney Cancer Association's Professional Group, discusses a new treatment for renal cancer that is being tested in a clinical trial.  For details of this trial please click here or visit ClinicalTrials.gov. 07/03/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 31, 2011 Category: Urology & Nephrology Source Type: news

Clinical Trial: Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
In this podcastBrian Rini, M.D., a member of the Kidney Cancer Association's Professional Group, discusses a new treatment for renal cancer that is being tested in a clinical trial.  For details of this trial pleaseclick here or visitClinicalTrials.gov.07/03/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 31, 2011 Category: Urology & Nephrology Source Type: news

Highlights From 2011 Genitourinary Cancers Symposium
An Evidence-based Multidisciplinary Approach February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Florida Links of interest from this meeting for people affected by renal cancers: 2011 Genitourinary Cancers Symposium Program Agenda General Poster Session D: Renal Cancer Best of Journals Articles Expert Editorial: Shifting Sands in the Clinical Management of the T1 Renal Mass Expert Editorial: The Role of Lymph Node Dissection in the Management of Renal Cell Carcinoma: Using Existing Data to Move Beyond “All or None” For the most accurate information from this meeting, we encourage readers to us...
Source: Kidney Cancer Association - February 27, 2011 Category: Urology & Nephrology Source Type: news

Highlights From 2011 Genitourinary Cancers Symposium
An Evidence-based Multidisciplinary ApproachFebruary 17-19, 2011 at the Orlando World Center Marriott in Orlando, FloridaLinks of interest from this meeting for people affected by renal cancers:2011 Genitourinary Cancers Symposium Program AgendaGeneral Poster Session D: Renal CancerBest of Journals ArticlesExpert Editorial: Shifting Sands in the Clinical Management of the T1 Renal MassExpert Editorial: The Role of Lymph Node Dissection in the Management of Renal Cell Carcinoma: Using Existing Data to Move Beyond“All or None”For the most accurate information from this meeting, we encourage readers to use these l...
Source: Kidney Cancer Association - February 27, 2011 Category: Urology & Nephrology Source Type: news

Journalists’ Award Supports Education About Renal Cancer
Raising awareness: Journalists’ Award supports education about renal cancer Bayer HealthCare and Kidney Cancer Association (KCA) honor outstanding medical reporting / Applications for European "Advances in Renal Cancer" Award can be submitted until March 1, 2011 Leverkusen, February 16, 2011 - According to current estimates of the European Cancer Observatory (ECO), each year more than 71,000 patients are newly-diagnosed with kidney cancer all over Europe.(1) With a mortality rate of over 40 percent, renal cell carcinoma is the most dangerous type of all urological tumors. That is why educating the public a...
Source: Kidney Cancer Association - February 23, 2011 Category: Urology & Nephrology Source Type: news

Journalists ’ Award Supports Education About Renal Cancer
Raising awareness: Journalists & rsquo; Award supports education about renal cancer Bayer HealthCare and Kidney Cancer Association (KCA) honor outstanding medical reporting / Applications for European & quot;Advances in Renal Cancer & quot; Award can be submitted until March 1, 2011 Leverkusen, February 16, 2011 - According to current estimates of the European Cancer Observatory (ECO), each year more than 71,000 patients are newly-diagnosed with kidney cancer all over Europe.(1) With a mortality rate of over 40 percent, renal cell carcinoma is the most dangerous type of all urological tumors. That is why edu...
Source: Kidney Cancer Association - February 23, 2011 Category: Urology & Nephrology Source Type: news

Journalists ’ Award Supports Education About Renal Cancer
Raising awareness: Journalists’ Award supports education about renal cancer Bayer HealthCare and Kidney Cancer Association (KCA) honor outstanding medical reporting / Applications for European"Advances in Renal Cancer" Award can be submitted until March 1, 2011 Leverkusen, February 16, 2011 - According to current estimates of the European Cancer Observatory (ECO), each year more than 71,000 patients are newly-diagnosed with kidney cancer all over Europe.(1) With a mortality rate of over 40 percent, renal cell carcinoma is the most dangerous type of all urological tumors. That is why educating the public abo...
Source: Kidney Cancer Association - February 23, 2011 Category: Urology & Nephrology Source Type: news

Endostatin- and interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinoma
Metastatic RCC (mRCC) is one of the most treatment-resistant malignancies02/24/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 23, 2011 Category: Cancer & Oncology Source Type: news

New limb sparing surgical techniques
This is a patient with a pathologic fracture of his right humerus due to metastatic renal cell carcinoma. Dr. Wittig and his team performed an intraarticular resection of the right proximal humerus.02/19/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2011 Category: Cancer & Oncology Source Type: news

ASPEN Clinical Trial
  ASPEN, a new investigator-initiated study being led by Duke University, is now enrolling patients with metastatic renal-cell carcinoma with non-clear cell histology.  Click here for more information. Listen to the podcast featuring lead investigator Andrew J. Armstrong, MD ScM, Assistant Professor of Medicine and Surgery at Duke Comprehensive Cancer Center, as he describes this trial.  Patients interested should refer to clinicaltrials.gov for the nearest open site.01/25/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 25, 2011 Category: Urology & Nephrology Source Type: news

ASPEN Clinical Trial
 ASPEN, a new investigator-initiated study being led by Duke University, is now enrolling patients with metastatic renal-cell carcinoma with non-clear cell histology. Click here for more information.Listen to the podcast featuring lead investigator Andrew J. Armstrong, MD ScM, Assistant Professor of Medicine and Surgery at Duke Comprehensive Cancer Center, as he describes this trial. Patients interested should refer toclinicaltrials.govfor the nearest open site.01/25/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 25, 2011 Category: Urology & Nephrology Source Type: news

Kidney Cancer Survival Rate Data
By: Neal Kennedy   To calculate the kidney cancer survival rate, you must take several different factors into consideration. Generally speaking, these factors are related to the patient who has been diagnosed with kidney cancer, and the kidney cancer stage.. In gathering their survival rate statistics, researchers take the type of cancer, stage, grade and location into consideration. Factors regarding the patient that must be considered include the individual's age, general health, and ability to undergo necessary treatment. Using data reflecting these factors in recent decades, medical researchers have been able to ...
Source: Kidney Cancer Association - November 23, 2010 Category: Urology & Nephrology Source Type: news

Kidney Cancer Survival Rate Data
By:Neal Kennedy To calculate the kidney cancer survival rate, you must take several different factors into consideration. Generally speaking, these factors are related to the patient who has been diagnosed with kidney cancer, and the kidney cancer stage..In gathering their survival rate statistics, researchers take the type of cancer, stage, grade and location into consideration. Factors regarding the patient that must be considered include the individual's age, general health, and ability to undergo necessary treatment.Using data reflecting these factors in recent decades, medical researchers have been able to genera...
Source: Kidney Cancer Association - November 23, 2010 Category: Urology & Nephrology Source Type: news

"Advances in Renal Cancer" Journalists' Award 2011 announced Bayer HealthCare and Kidney Cancer Association (KCA) honor medical reporting about renal cancer
Leverkusen, July 2010 - Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European "Advances in Renal Cancer" Journalists’ Award 2011. For the third time, the prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print media, radio, television, or film. "Malignant tumors in kidney...
Source: Kidney Cancer Association - August 6, 2010 Category: Urology & Nephrology Source Type: news

"Advances in Renal Cancer" Journalists' Award 2011 announced Bayer HealthCare and Kidney Cancer Association (KCA) honor medical reporting about renal cancer
Leverkusen, July 2010 - Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European"Advances in Renal Cancer" Journalists’ Award 2011. For the third time, the prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print media, radio, television, or film."Malignant tumors in kidney ce...
Source: Kidney Cancer Association - August 6, 2010 Category: Urology & Nephrology Source Type: news

Patient reported side effects from molecularly targeted therapies in renal cell carcinoma
Conclusions: These results suggest that the patient-reported impact of molecularly targeted agent side effects may be more significant than suggested by phase III clinical trials. These results also identify specific side effects towards which improved symptom management strategies and enhanced patient education can be directed. Better side effect management may increase treatment duration and improve clinical outcomes. 06/25/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 25, 2010 Category: Urology & Nephrology Source Type: news

Patient reported side effects from molecularly targeted therapies in renal cell carcinoma
Conclusions:These results suggest that the patient-reported impact of molecularly targeted agent side effects may be more significant than suggested by phase III clinical trials. These results also identify specific side effects towards which improved symptom management strategies and enhanced patient education can be directed. Better side effect management may increase treatment duration and improve clinical outcomes.06/25/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 25, 2010 Category: Urology & Nephrology Source Type: news

Distant Metastasis of Renal Cell Carcinoma With a Diameter of 3 cm or Less —Which is Aggressive Cancer
Metastasis develops in small renal cell carcinoma cases. Results suggest that microvascular invasion is a significant risk factor and patients with microvascular invasion should be followed more carefully. 06/19/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 19, 2010 Category: Urology & Nephrology Source Type: news

AVEO Pharmaceuticals ’ Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorab
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months. 06/10/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 9, 2010 Category: Urology & Nephrology Source Type: news

"Advances in Renal Cancer" Journalists' Award 2011 announced
Leverkusen, May 2010 – Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European “Advances in Renal Cancer” Journalists’ Award 2011. For the third time, the prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print media, radio, television, or film. "Malignant tumors in...
Source: Kidney Cancer Association - June 2, 2010 Category: Urology & Nephrology Source Type: news

"Advances in Renal Cancer" Journalists' Award 2011 announced
Leverkusen, May 2010– Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European“Advances in Renal Cancer” Journalists’ Award 2011. For the third time, the prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print media, radio, television, or film."Malignant tumors in kid...
Source: Kidney Cancer Association - June 2, 2010 Category: Urology & Nephrology Source Type: news

Evaluation of neuroendocrine markers in renal cell carcinoma
Tumours with an immunopositivity for serotonin had a longer RCC–specific survival and tumours with an immunopositivity for CD56 and NSE had a shorter RCC–specific survival but the difference was not significant.05/27/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 27, 2010 Category: Urology & Nephrology Source Type: news

Evaluation of neuroendocrine markers in renal cell carcinoma
Tumours with an immunopositivity for serotonin had a longer RCC –specific survival and tumours with an immunopositivity for CD56 and NSE had a shorter RCC–specific survival but the difference was not significant.05/27/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 27, 2010 Category: Urology & Nephrology Source Type: news

IMBiotechnologies Receives FDA Clearance to Market Occlusin ® 500 Biodegradable Microspheres in the U.S.
OCL 500 is a microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids. 05/17/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 17, 2010 Category: Urology & Nephrology Source Type: news

New Oral VEGF-TKI, Tivozanib, Demonstrates Robust Anti-tumor Activity and Excellent Safety in Advanced Kidney Cancer Patients – Global Phase 3 TIVO-1 Trial Actively Recruiting
AVEO Pharmaceuticals has recently initiated enrollment in a Phase 3 clinical trial evaluating tivozanib – a new oral, once-daily, triple VEGF receptor inhibitor – in patients with advanced kidney cancer, with nearly 500 patients worldwide expected to participate. TIVO-1 is a randomized, controlled trial evaluating tivozanib compared to sorafenib (Nexavar®), an FDA and EMEA approved therapy for the treatment of advanced renal cell carcinoma (RCC). The primary endpoint of the trial is progression-free survival (PFS), while secondary endpoints include overall survival, objective response rate, duration of resp...
Source: Kidney Cancer Association - April 29, 2010 Category: Urology & Nephrology Source Type: news

New Oral VEGF-TKI, Tivozanib, Demonstrates Robust Anti-tumor Activity and Excellent Safety in Advanced Kidney Cancer Patients – Global Phase 3 TIVO-1 Trial Actively Recruiting
AVEO Pharmaceuticals has recently initiated enrollment in a Phase 3 clinical trial evaluating tivozanib– a new oral, once-daily, triple VEGF receptor inhibitor– in patients with advanced kidney cancer, with nearly 500 patients worldwide expected to participate. TIVO-1 is a randomized, controlled trial evaluating tivozanib compared to sorafenib (Nexavar®), an FDA and EMEA approved therapy for the treatment of advanced renal cell carcinoma (RCC). The primary endpoint of the trial is progression-free survival (PFS), while secondary endpoints include overall survival, objective response rate, duration of respon...
Source: Kidney Cancer Association - April 29, 2010 Category: Urology & Nephrology Source Type: news